SCHEMBL19945896

SCHEMBL19945896

CCOC(=O)OCOC(=O)c1ccc(NC(=O)OC(C)(C)C)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDK1 Q15118 1/20 0.50
PDK2 Q15119 1/20 0.50
PDK3 Q15120 1/20 0.50
PDK4 Q16654 1/20 0.50
RAB9A P51151 8/20 0.49
NPC1 O15118 5/20 0.49
MAPT P10636 5/20 0.49
NPSR1 Q6W5P4 2/20 0.49
TSHR P16473 2/20 0.49
NAMPT P43490 2/20 0.48
MEN1 O00255 4/20 0.48
KMT2A Q03164 4/20 0.48
SMN1; SMN2 Q16637 6/20 0.48
GAA P10253 3/20 0.48
CASP3 P42574 1/20 0.48
TRPV1 Q8NER1 1/20 0.48
SENP7 Q9BQF6 1/20 0.48
TP53 P04637 1/20 0.48
POLB P06746 1/20 0.48
MAPK1 P28482 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL273218 0.89 PDK1 (0.60) PDK1PDK2PDK3PDK4RAB9A
SCHEMBL8728009 0.83 CYP17A1 (0.60) PDK1PDK2PDK3PDK4RAB9A
SCHEMBL25736767 0.77 RAB9A (0.51) PDK1PDK2PDK3PDK4RAB9A
SCHEMBL4315966 0.77 MEN1 (0.59) RAB9ANPC1MAPTNAMPTMEN1
SCHEMBL25012380 0.77 HPGD (0.61) RAB9ANPC1MAPTNPSR1TSHR
SCHEMBL7143564 0.77 MEN1 (0.64) PDK1PDK2PDK3PDK4RAB9A
SCHEMBL2349306 0.76 PDK1 (0.46) PDK1PDK2PDK3PDK4RAB9A
SCHEMBL10941324 0.76 NAMPT (0.69) RAB9ANPC1MAPTTSHRNAMPT
SCHEMBL7477944 0.75 KMT2A (0.66) RAB9ANPC1MAPTNPSR1NAMPT
SCHEMBL13055402 0.75 CYP17A1 (0.59) NAMPTSMN1; SMN2GAAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3486242-B1 OXOPICOLINAMIDE DERIVATIVE, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF JIANGSU HENGRUI MEDICINE CO (CN) 2021-12-08 EP disclosed
US-11084808-B2 Oxopicolinamide derivative, preparation method therefor and pharmaceutical use thereof JIANGSU HENGRUI MEDICINE CO., LTD. (CN) 2021-08-10 US disclosed
US-20200199115-A1 OXOPICOLINAMIDE DERIVATIVE, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) 2020-06-25 US disclosed
US-10633375-B2 Oxopicolinamide derivative, preparation method therefor and pharmaceutical use thereof Jinagsu Hengrui Medicine Co., Ltd (CN) 2020-04-28 US disclosed
US-20190185464-A1 OXOPICOLINAMIDE DERIVATIVE, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF JIANGSU HENGRUI MEDICINE CO., LTD. (CN) 2019-06-20 US disclosed
EP-3486242-A1 OXOPICOLINAMIDE DERIVATIVE, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF Jiangsu Hengrui Medicine Co., Ltd. (CN) 2019-05-22 EP disclosed
WO-2018041122-A1 OXOPICOLINAMIDE DERIVATIVE, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF 江苏恒瑞医药股份有限公司 2018-03-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10633375-B2 Oxopicolinamide derivative, preparation method therefor and pharmaceutical use thereof F11, F2, F7 PDK1 876/4885PDK2 1186/4885PDK3 2286/4885
US-20200199115-A1 OXOPICOLINAMIDE DERIVATIVE, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF F11, F2, F7 PDK1 697/4885PDK2 1149/4885PDK3 2461/4885
US-20190185464-A1 OXOPICOLINAMIDE DERIVATIVE, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF F11, F2, F7 PDK1 876/4885PDK2 1186/4885PDK3 2286/4885
US-11084808-B2 Oxopicolinamide derivative, preparation method therefor and pharmaceutical use thereof F11, F2, F7 PDK1 876/4885PDK2 1186/4885PDK3 2286/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.